Summary
Non-HDL cholesterol is calculated as total cholesterol minus HDL cholesterol. It captures all atherogenic cholesterol — including LDL, VLDL, IDL, and remnant particles — in a single number. Non-HDL is increasingly preferred over LDL alone as a cardiovascular risk target because it is accurate without fasting, more predictive in people with high triglycerides, and captures the full atherogenic lipoprotein spectrum.
LDL cholesterol is the traditional cardiovascular risk target, but it misses the cholesterol carried in VLDL, IDL, and remnant particles — which are also atherogenic. Non-HDL cholesterol includes all of these in one calculation: total cholesterol − HDL.
Non-HDL has several advantages: it does not require fasting (unlike triglycerides); it is more predictive than LDL in people with metabolic syndrome or diabetes (where triglyceride-rich remnant particles substantially contribute to risk); and it correlates more closely with ApoB than LDL-C does.
NICE guidelines recommend non-HDL as the primary lipid treatment target in high-risk patients, with a target < 3.4 mmol/L for primary prevention and < 2.5 mmol/L for secondary prevention (established CVD).
What It Is
Non-HDL cholesterol is calculated as: total cholesterol (mmol/L) − HDL cholesterol (mmol/L). It encompasses the cholesterol carried in: LDL (the primary atherogenic fraction); VLDL (triglyceride-rich, liver-derived); IDL (intermediate density — LDL precursors); and Lp(a) particles.
This makes non-HDL equivalent to the total cholesterol content of all atherogenic particles — and closely correlated with ApoB (particle number). Meta-analyses of cardiovascular risk prediction studies consistently show non-HDL is a stronger predictor of cardiovascular events than LDL-C alone, particularly in the non-fasting setting.
Target values: primary prevention (no CVD) < 3.8 mmol/L; high risk < 3.4 mmol/L; very high risk (established CVD) < 2.5 mmol/L (NICE/ESC). Non-HDL target is always 0.8 mmol/L higher than the corresponding LDL target.
Functions
Complete atherogenic burden capture
Non-HDL captures cholesterol from all atherogenic particles — LDL, VLDL, IDL, and remnants — not just LDL.
Fasting-independent risk measure
Non-HDL is valid whether fasting or non-fasting — making it practical for opportunistic cardiovascular screening.
Superior marker in metabolic syndrome
In people with high triglycerides, non-HDL better captures the full atherogenic risk from remnant particles that LDL underestimates.
NICE primary prevention target
NICE guidelines (CG181) recommend non-HDL as the primary cardiovascular prevention target — with a goal < 3.8 mmol/L for most adults.
Reference Ranges
Non-HDL Cholesterol
Measured in mmol/L| Status | Range (mmol/L) | Range (mg/dL) | What it means |
|---|---|---|---|
| Optimal | < 3.8 | < 147 | Low atherogenic particle burden — NICE primary prevention target. |
| Borderline | 3.8–4.9 | 147–190 | Elevated — assess cardiovascular risk and optimise lifestyle. |
| High | 5.0–6.4 | 190–247 | Significantly elevated — cardiovascular risk management indicated. |
| Very high | ≥ 6.5 | ≥ 250 | Very high atherogenic burden — urgent lipid management and cardiovascular risk review. |
Non-HDL targets depend on risk level: primary prevention < 3.8 mmol/L; high risk (10-year CVD risk ≥ 10%) < 3.4 mmol/L; established CVD < 2.5 mmol/L (NICE). Non-HDL is 0.8 mmol/L higher than the corresponding LDL target.
Symptoms of Imbalance
Elevated non-HDL is asymptomatic — the clinical consequence is progressive atherosclerosis over years.
- Very low non-HDL (from aggressive lipid-lowering therapy) is well tolerated in clinical trials.
- Asymptomatic for years to decades
- Tendon xanthomata and xanthelasma in severe elevation (familial hypercholesterolaemia)
- Eventual symptoms of coronary artery disease (angina, breathlessness)
Causes of Imbalance
- Statin or PCSK9 inhibitor therapy
- Very low fat diet
- Hyperthyroidism
- Familial hypercholesterolaemia
- Metabolic syndrome and insulin resistance (VLDL/remnant excess)
- Type 2 diabetes
- Obesity
- Hypothyroidism
- Chronic kidney disease
- High saturated fat diet
FAQs
LDL cholesterol measures only the cholesterol in low-density lipoprotein particles. Non-HDL cholesterol = total cholesterol − HDL and includes LDL plus cholesterol in VLDL, IDL, and remnant particles. In people with high triglycerides (where VLDL is elevated), non-HDL captures more of the true atherogenic risk than LDL alone. NICE now recommends non-HDL as the primary treatment target.
Yes — this is a key advantage of non-HDL over LDL and triglycerides. Because non-HDL = total cholesterol − HDL, and neither of these is significantly affected by a recent meal (unlike triglycerides), non-HDL is valid in both fasting and non-fasting samples. This makes it ideal for opportunistic cardiovascular screening at any time of day.
NICE recommends: < 3.8 mmol/L for primary prevention in adults without cardiovascular disease; < 3.4 mmol/L for those with a 10-year CVD risk ≥ 10%; < 2.5 mmol/L for people with established cardiovascular disease (post-heart attack, stroke, or peripheral artery disease). Each of these is 0.8 mmol/L higher than the corresponding LDL target.
People with type 2 diabetes and metabolic syndrome typically have elevated VLDL and triglyceride-rich remnant particles alongside LDL. These remnant particles are atherogenic but are not captured by LDL-C measurement. Non-HDL includes all of these atherogenic fractions, providing a more complete and accurate measure of cardiovascular risk in this common population.
References
- NICE. Cardiovascular disease: risk assessment and reduction, including lipid modification. CG181. Updated 2023. View source
- Boekholdt SM, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins. JAMA. 2012;307(12):1302–1309. View source
- Nordestgaard BG, et al. Fasting is not routinely required for determination of a lipid profile. Eur Heart J. 2016;37(25):1944–1953. View source